| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
10,11-Dehydrocurvularin targets the NLRP3 inflammasome, functioning as a specific inhibitor of NLRP3 inflammasome activation. Aberrant activation of the NLRP3 inflammasome is involved in diverse inflammation-related diseases. DCV specifically inhibits NLRP3 inflammasome activation in association with reduced IL-1β secretion and caspase-1 activation, without effect on the NLRC4 and AIM2 inflammasomes. The C=C double bond of DCV is required for its NLRP3 inflammasome inhibition. DCV also inhibits the TGF-β signaling pathway, demonstrating anti-tumorigenic properties.
|
|---|---|
| ln Vitro |
In vitro, 10,11-Dehydrocurvularin specifically inhibits the activation of the NLRP3 inflammasome, leading to reduced IL-1β secretion and caspase-1 activation, without affecting NLRC4 and AIM2 inflammasomes. The compound disturbs the interaction between NEK7 and NLRP3, resulting in inhibition of NLRP3 inflammasome activation. The C=C double bond of DCV is required for this inhibitory activity. DCV also exhibits significant inhibition of the TGF-β signaling pathway, demonstrating anti-tumorigenic properties. It has been shown to activate the heat shock response and inhibit cell division by disrupting mitotic spindle formation.
|
| ln Vivo |
In vivo, 10,11-Dehydrocurvularin ameliorates inflammation through inhibiting the NLRP3 inflammasome. The compound's anti-inflammatory activity has been demonstrated in relevant animal models. DCV also exhibits anti-tumorigenic properties through inhibition of the TGF-β signaling pathway. It shows potential for agricultural and pharmaceutical uses. Further in vivo studies are needed to fully characterize its efficacy and safety across different disease models. The compound is a natural-product macrolide with demonstrated in vivo efficacy in inflammation models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 10,11-Dehydrocurvularin typically involve assessing its interaction with NLRP3 inflammasome components. The compound's ability to disturb the NEK7-NLRP3 interaction is evaluated using co-immunoprecipitation or pull-down assays. Binding affinity to NLRP3 or NEK7 can be assessed using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). The C=C double bond of DCV is required for NLRP3 inflammasome inhibition, as confirmed through structure-activity relationship studies using DCV analogs. Assays are conducted in buffered solutions at physiological pH with appropriate protein preparations.
|
| Cell Assay |
In vitro cell-based assays for 10,11-Dehydrocurvularin utilize macrophages or other immune cells to assess its effects on NLRP3 inflammasome activation. Cells are treated with varying concentrations of DCV prior to stimulation with NLRP3 activators such as nigericin or ATP. IL-1β secretion is measured by ELISA, and caspase-1 activation is assessed by Western blot or fluorometric assays. The compound's effect on NEK7-NLRP3 interaction is evaluated by co-immunoprecipitation. Specificity for NLRP3 over NLRC4 and AIM2 inflammasomes is confirmed through parallel experiments. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed.
|
| Animal Protocol |
In vivo animal studies with 10,11-Dehydrocurvularin typically involve administration of the compound to rodent models of NLRP3 inflammasome-driven inflammatory disorders. The compound ameliorates inflammation in vivo through inhibiting the NLRP3 inflammasome. Potential study designs include models of peritonitis, colitis, or other inflammatory conditions where NLRP3 plays a role. Endpoints include measurements of IL-1β and other inflammatory cytokines in serum and tissues, assessment of tissue pathology, and evaluation of immune cell infiltration. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for 10,11-Dehydrocurvularin are not extensively documented in the publicly available literature. The compound has a molecular weight of 290.31 g/mol and a molecular formula of C₁₆H₁₈O₅. It is soluble in ethanol, methanol, DMF, and DMSO. As a natural product macrolide, its oral bioavailability would be influenced by factors such as intestinal absorption and first-pass metabolism. The compound is typically stored under conditions recommended for natural product research chemicals. Further studies are needed to characterize its pharmacokinetic profile.
|
| Toxicity/Toxicokinetics |
10,11-Dehydrocurvularin is intended for research use only and is not approved for human therapeutic applications. As a natural product research chemical, comprehensive toxicological data are not extensively documented in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. As with all research chemicals, comprehensive toxicological profiling would be required before any consideration for clinical development. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| References |
|
| Additional Infomation |
α,β-Dehydroaspergillus is a macrolide antibiotic. α,β-Dehydroaspergillus has been reported to be detected in Aspergillus terreus, and relevant data are available for reference.
10,11-Dehydrocurvularin (CAS#: 21178-57-4) has a molecular formula of C₁₆H₁₈O₅ and a molecular weight of 290.31 g/mol. It is a naturally occurring benzenediol lactone (BDL) with a 12-membered macrolide fused to a resorcinol ring, produced as a secondary metabolite by many fungi. DCV is an antibiotic that inhibits cell division by disrupting mitotic spindle formation and activates the heat shock response. It specifically inhibits NLRP3 inflammasome activation by disturbing the NEK7-NLRP3 interaction, without affecting NLRC4 and AIM2 inflammasomes. DCV also inhibits TGF-β signaling and demonstrates anti-tumorigenic properties. This compound is not a drug and has not undergone clinical trials. |
| Molecular Formula |
C16H18O5
|
|---|---|
| Molecular Weight |
290.31
|
| Exact Mass |
290.115
|
| CAS # |
21178-57-4
|
| Related CAS # |
(R)-10,11-Dehydrocurvularin;1095588-70-7
|
| PubChem CID |
14314897
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.225 g/cm3
|
| Boiling Point |
576.3ºC at 760 mm
|
| Flash Point |
216.7ºC
|
| Vapour Pressure |
7.02E-14mmHg at 25°C
|
| Index of Refraction |
1.555
|
| LogP |
2.494
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
21
|
| Complexity |
417
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1CCC/C=C/C(=O)C2=C(CC(=O)O1)C=C(C=C2O)O
|
| InChi Key |
AVIRMQMUBGNCKS-GQCTYLIASA-N
|
| InChi Code |
InChI=1S/C16H18O5/c1-10-5-3-2-4-6-13(18)16-11(8-15(20)21-10)7-12(17)9-14(16)19/h4,6-7,9-10,17,19H,2-3,5,8H2,1H3/b6-4+
|
| Chemical Name |
(9E)-13,15-dihydroxy-5-methyl-4-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraene-3,11-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4446 mL | 17.2230 mL | 34.4459 mL | |
| 5 mM | 0.6889 mL | 3.4446 mL | 6.8892 mL | |
| 10 mM | 0.3445 mL | 1.7223 mL | 3.4446 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
